Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review

Overview

Journal Adv Ther

Date 2023 May 26

PMID 37233876

Authors

Stephanie Korn

Bill Cook

Lisa J Simpson

Jean-Pierre Llanos

Christopher S Ambrose

Affiliations

Soon will be listed here.

Abstract

Introduction: Randomized controlled trials (RCTs) of biologics in patients with severe, uncontrolled asthma have shown differential results by baseline blood eosinophil count (BEC). In the absence of head-to-head trials, we describe the effects of biologics on annualized asthma exacerbation rate (AAER) by baseline BEC in placebo-controlled RCTs. Exacerbations associated with hospitalization or an emergency room visit, pre-bronchodilator forced expiratory volume in 1 s, Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score were also summarized.

Methods: MEDLINE (via PubMed) was searched for RCTs of biologics in patients with severe, uncontrolled asthma and with AAER reduction as a primary or secondary endpoint. AAER ratios and change from baseline in other outcomes versus placebo were compared across baseline BEC subgroups. Analysis was limited to US Food and Drug Administration-approved biologics.

Results: In patients with baseline BEC ≥ 300 cells/μL, AAER reduction was demonstrated with all biologics, and other outcomes were generally improved. In patients with BEC 0 to < 300 cells/μL, consistent AAER reduction was demonstrated only with tezepelumab; improvements in other outcomes were inconsistent across biologics. In patients with BEC 150 to < 300 cells/μL, consistent AAER reduction was demonstrated with tezepelumab and dupilumab (300 mg dose only), and in those with BEC 0 to < 150 cells/μL, AAER reduction was demonstrated only with tezepelumab.

Conclusion: The efficacy of all biologics in reducing AAER in patients with severe asthma increases with higher baseline BEC, with varying profiles across individual biologics likely due to differing mechanisms of action.

Citing Articles

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA.

Settipane R, Germain G, Laliberte F, Mahendran M, Hilts A, Duh M Pulm Ther. 2025; 11(1):81-100.

PMID: 39869154 PMC: 11861473. DOI: 10.1007/s41030-024-00285-9.

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.

Panettieri Jr R, Lugogo N, Corren J, Ambrose C J Asthma Allergy. 2024; 17:219-236.

PMID: 38524099 PMC: 10960583. DOI: 10.2147/JAA.S342391.

Severe Asthma and Biological Therapies: Now and the Future.

Sardon-Prado O, Diaz-Garcia C, Corcuera-Elosegui P, Korta-Murua J, Valverde-Molina J, Sanchez-Solis M J Clin Med. 2023; 12(18).

PMID: 37762787 PMC: 10532431. DOI: 10.3390/jcm12185846.

References

Bourdin A, Molinari N, Vachier I, Pahus L, Suehs C, Chanez P . Mortality: a neglected outcome in OCS-treated severe asthma. Eur Respir J. 2017; 50(5). DOI: 10.1183/13993003.01486-2017. View

Ortega H, Yancey S, Mayer B, Gunsoy N, Keene O, Bleecker E . Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549-556. DOI: 10.1016/S2213-2600(16)30031-5. View

Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View

Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica G . Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe.... Allergy. 2020; 75(5):1023-1042. DOI: 10.1111/all.14221. View

Yancey S, Bradford E, Keene O . Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL. Respir Med. 2019; 151:139-141. DOI: 10.1016/j.rmed.2019.04.008. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Bleecker E, FitzGerald J, Chanez P, Papi A, Weinstein S, Barker P . Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056):2115-2127. DOI: 10.1016/S0140-6736(16)31324-1. View

Harrison T, Chanez P, Menzella F, Canonica G, Louis R, Cosio B . Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2020; 9(3):260-274. DOI: 10.1016/S2213-2600(20)30414-8. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

10.

OQuinn S, Xu X, Hirsch I . Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. J Asthma Allergy. 2019; 12:21-33. PMC: 6350639. DOI: 10.2147/JAA.S190221. View

11.

FitzGerald J, Bleecker E, Menzies-Gow A, Zangrilli J, Hirsch I, Metcalfe P . Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2017; 6(1):51-64. DOI: 10.1016/S2213-2600(17)30344-2. View

12.

Marone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S . The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma. Front Pharmacol. 2019; 10:1387. PMC: 6908970. DOI: 10.3389/fphar.2019.01387. View

13.

Sverrild A, Hansen S, Hvidtfeldt M, Clausson C, Cozzolino O, Cerps S . The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021; 59(1). DOI: 10.1183/13993003.01296-2021. View

14.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

15.

Hanania N, Alpan O, Hamilos D, Condemi J, Reyes-Rivera I, Zhu J . Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011; 154(9):573-82. DOI: 10.7326/0003-4819-154-9-201105030-00002. View

16.

Gauvreau G, OByrne P, Boulet L, Wang Y, Cockcroft D, Bigler J . Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014; 370(22):2102-10. DOI: 10.1056/NEJMoa1402895. View

17.

Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L . Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017; 5(5):390-400. DOI: 10.1016/S2213-2600(17)30125-X. View

18.

Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View

19.

Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M . Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020; 29(156). PMC: 9488652. DOI: 10.1183/16000617.0137-2019. View

20.

Bleecker E, Wechsler M, FitzGerald J, Menzies-Gow A, Wu Y, Hirsch I . Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018; 52(4). PMC: 6203407. DOI: 10.1183/13993003.00936-2018. View